Telix Pharmaceuticals Shares Given Aggressive Price Target, as New Bull Emerges

Telix Pharmaceuticals shares (ASX:TLX) have gained a new bull on Wall Street, giving beleaguered holders something to rally to behind, after a 50% drawdown over the past 12 months.

JPMorgan has initiated coverage of  TLX with an Overweight rating and A$23.60 price target, marking a significant vote of confidence in the company as it navigates multiple regulatory catalysts that could unlock substantial value over the coming months.

The Telix Pharmaceuticals share price has begun June trading at A$13.02, reflecting a modest 0.08% decline, yet sitting nearly 80% below JPMorgan’s newly established price target.

The valuation gap represents one of the largest among ASX-listed biotechnology companies with established commercial operations, signalling that markets are either pricing in significant execution risk or presenting a compelling opportunity for patient capital, depending on one’s view of the company’s regulatory prospects.

The stock has experienced elevated volatility in recent months as it works through a complex set of FDA interactions, legal scrutiny, and pipeline milestones. Despite the challenges, multiple Wall Street and Australian brokers have maintained positive ratings, with JPMorgan now joining a growing chorus of bulls who see the current valuation as disconnected from the company’s commercial momentum and late-stage pipeline potential.

Tailwinds Driving The Price Target

JPMorgan’s bullish stance centres on what the firm describes as “structural tailwinds” benefiting radioligand therapies, a rapidly evolving field that combines precision imaging with targeted radiation treatment for cancer. The analyst team pointed to Telix’s established commercial footprint in diagnostic imaging agents and its diversified late-stage therapeutic pipeline as key differentiators in a space attracting increasing interest from major pharmaceutical companies.

The firm highlighted three specific near-term catalysts that could materially re-rate the stock:

First, the potential FDA clearance for TLX-591 to advance into the randomized Part 2 phase of its ProstACT Global trial. This Phase 3 programme targets metastatic castration-resistant prostate cancer and represents Telix’s lead therapeutic candidate. In December 2025, the company announced a clinical collaboration with Varian to combine its theranostic approach with external beam radiation therapy, broadening the potential clinical and commercial impact of the programme.

Second, the resubmission of the Biologics License Application for Zircaix (TLX250-CDx), a renal cancer imaging agent that received a Complete Response Letter from the FDA over manufacturing and supply-chain concerns. Telix has since held two Type A meetings with regulators and disclosed in its FY2025 results that it has “aligned on key outstanding issues” related to comparability between clinical trial material and scaled commercial product. This progress suggests the regulatory path forward is becoming clearer, though not without residual risk.

Third, and perhaps most immediately, the FDA action date of September 11 for Pixclara, Telix’s brain imaging agent. The agency has accepted the company’s resubmitted New Drug Application, setting up a binary event that will test both Telix’s regulatory execution capabilities and the FDA’s appetite for novel radiopharmaceutical diagnostics. Success here would validate the company’s broader precision-imaging franchise and strengthen confidence across the entire pipeline.

Financials Supportive

Telix reported robust financial results for FY2025, with revenue surging 56% to approximately US$804 million, driven primarily by strong uptake of Illuccix, its prostate cancer imaging agent that has become a commercial anchor for the business. The company generated positive adjusted operating cash flow, though it recorded a small pre-tax loss due to elevated research and development spending of roughly US$194 million and non-cash finance charges.

The heavy R&D investment reflects management’s commitment to advancing multiple late-stage assets simultaneously across both therapeutic and diagnostic programmes. Bulls view this spending as value-accretive given the breadth of the pipeline and the potential to leverage existing manufacturing and commercial infrastructure across multiple radioligands. Bears, however, point to the deferred profitability and rising operating costs as reasons for caution, particularly if regulatory approvals are delayed or come with restrictive labeling.

The company’s balance sheet received a boost in recent months through a strategic collaboration with Regeneron Pharmaceuticals, which included a US$40 million upfront payment to co-develop next-generation radiopharmaceutical therapies. The deal provides non-dilutive funding and represents strong validation from a top-tier U.S. biotechnology company, reinforcing JPMorgan’s thesis that Telix’s platform has strategic value beyond its current pipeline.

The market structure heading into the September Pixclara decision is likely to be characterised by elevated volatility, with event-driven capital and options positioning amplifying moves in either direction. A clean approval would likely trigger a sharp bounce and could catalyse a broader reassessment of the pipeline’s risk profile. On the other hand, another delay or restrictive labelling would reinforce concerns about Telix’s ability to navigate the FDA’s increasingly stringent standards for radiopharmaceuticals.